[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503007":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":46,"centralContacts":50,"locations":55,"responsibleParty":73,"collaborators":75,"id":79,"slug":30,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":30,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":30,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":30,"overallStatus":58,"whyStopped":30,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Suvorexant (20mg\u002Fday)","EXPERIMENTAL","Double blind administration of suvorexant once per day during residential stay until discharge",[13,14,15,16,17],"Drug: Drug A (Blinded Drug)","Drug: Drug B (Blinded Drug)","Drug: Drug C (Blinded Drug)","Drug: Drug D (Blinded Drug)","Drug: Suvorexant (20mg\u002Fday)",{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Double blind administration of placebo once per day during residential stay until discharge",[13,14,15,16,23],"Drug: Placebo",[25,31,34,37,40,43],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Drug A (Blinded Drug)","Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).",[19,9],null,{"type":26,"name":32,"description":28,"armGroupLabels":33,"otherNames":30},"Drug B (Blinded Drug)",[19,9],{"type":26,"name":35,"description":28,"armGroupLabels":36,"otherNames":30},"Drug C (Blinded Drug)",[19,9],{"type":26,"name":38,"description":28,"armGroupLabels":39,"otherNames":30},"Drug D (Blinded Drug)",[19,9],{"type":26,"name":9,"description":41,"armGroupLabels":42,"otherNames":30},"Double blind administration of suvorexant once per day during residential stay until discharge.",[9],{"type":26,"name":19,"description":44,"armGroupLabels":45,"otherNames":30},"Double blind administration of placebo once per day during residential stay until discharge.",[19],[47],{"name":48,"affiliation":5,"role":49},"Justin Strickland, PhD","PRINCIPAL_INVESTIGATOR",[51],{"name":48,"role":52,"phone":53,"phoneExt":30,"email":54},"CONTACT","667-354-3516","jstrickland@som.umaryland.edu",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"General Clinical Research Center","RECRUITING","Baltimore","Maryland","21201","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-76.61219,39.29038,{"lat":68,"lon":67},[71,72],{"name":48,"role":52,"phone":53,"phoneExt":30,"email":54},{"name":48,"role":49,"phone":30,"phoneExt":30,"email":30},{"type":74,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[76],{"name":77,"class":78},"National Institute on Drug Abuse (NIDA)","NIH","100503007",false,"NCT05829655","Measuring Acute Drug Demand in Humans","Inclusion Criteria:\n\n* Age between 18 and 65 years old\n* Meets Diagnostic and Statistical Manual-5 criteria for Opioid Use Disorder (OUD) (moderate or severe)\n* Lifetime substance use history criterion \\[blinded\\]\n* Medically cleared to take suvorexant and blinded study medications\n* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n\nExclusion Criteria:\n\n* Pregnant or breast feeding\n* Seeking opioid use treatment\n* Significant mental health or physical disorder that is expected to interfere with study participation as assessed by the study physicians or medical staff\n* Known contraindications or allergies to suvorexant and\u002For the blinded study medications",true,"ALL","18 Years","65 Years",{"count":89,"type":90},75,"ESTIMATED","INTERVENTIONAL",[93],"EARLY_PHASE1","This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.",[96,97],"Opioid Use Disorder","Opioid Dependence","2026-06-19",{"date":100,"type":101},"2026-06-23","ACTUAL",{"date":103,"type":101},"2023-08-08",{"date":105,"type":90},"2028-01-01",{"name":5,"class":6},1]